Pharmacokinetics and therapeutic drug monitoring of anticancer protein/kinase inhibitors
| dc.rights.license | open | en_US |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BOUCHET, Stephane | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MOLIMARD, Mathieu | |
| dc.date.accessioned | 2022-05-16T12:34:44Z | |
| dc.date.available | 2022-05-16T12:34:44Z | |
| dc.date.issued | 2022-03 | |
| dc.identifier.issn | 1958-5578 (Electronic) 0040-5957 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/140071 | |
| dc.description.abstractEn | Over the past two decades, protein/kinase inhibitors, as targeted therapies, raised in number and have become increasingly mainstream in the treatment of malignant diseases, thanks to the ease of oral administration and the minimal adverse drug reactions. These drugs have similar pharmacokinetic properties: a relatively good absorption and distribution, a strong hepatic metabolism, and a mainly biliary excretion. However, this pharmacokinetic and route of administration has the disadvantage of resulting in a large inter- and intra-individual variability. Despite this significant variability, these drugs are largely prescribed at the same initial dose for quite all patients (flat dose), even though this variability would require individualized adaptation for each patient and/or each new circumstance. Promptly after their commercialization, scientific teams have performed concentration measurements of several drugs and showed the existence of efficacy or toxicity thresholds. This has contributed to the development of therapeutic drug monitoring as one of the strategies to improve the response and reduce the adverse reactions of these drugs. There is still a need to determine precise thresholds for the remaining drugs and to evaluate the impact of TDM in therapeutic management. In order to determine the current state of the art, this article reviews indications, pharmacokinetics and TDM data for 49 marketed PKIs. © 2021 Société française de pharmacologie et de thérapeutique | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Therapeutic drug monitoring | |
| dc.subject.en | Protein/kinase inhibitors | |
| dc.subject.en | Cancer drugs | |
| dc.title.en | Pharmacokinetics and therapeutic drug monitoring of anticancer protein/kinase inhibitors | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.therap.2021.12.002 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 35101282 | en_US |
| bordeaux.journal | Thérapie | en_US |
| bordeaux.page | 157-170 | en_US |
| bordeaux.volume | 77 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 2 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | AHEAD_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03669204 | |
| hal.version | 1 | |
| hal.date.transferred | 2022-05-16T12:34:46Z | |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Th%C3%A9rapie&rft.date=2022-03&rft.volume=77&rft.issue=2&rft.spage=157-170&rft.epage=157-170&rft.eissn=1958-5578%20(Electronic)%200040-5957%20(Linking)&rft.issn=1958-5578%20(Electronic)%200040-5957%20(Linking)&rft.au=BOUCHET,%20Stephane&MOLIMARD,%20Mathieu&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||